November 6, 2025

Launching the first large-scale scientific initiative combining frontier AI with frontier biology to solve disease

To power this initiative, we are uniting our scientific teams as a single organization: Biohub.

398 Results
  • Axios: Zuckerberg and Chan bet AI can cure all disease

  • Associated Press: Zuckerberg, Chan shift bulk of philanthropy to science, focusing on AI and biology to curb disease

  • Science: AI drives dramatic expansion of Chan Zuckerberg Initiative’s funding to end all diseases

  • Latent Space: Priscilla Chan and Mark Zuckerberg — Frontier AI + virtual biology to solve all diseases

  • a16z Podcast: Mark Zuckerberg & Priscilla Chan — How AI will cure all disease

  • Biohub launches first large-scale scientific initiative combining frontier AI with frontier biology to cure or prevent disease

    Biohub to unite data, compute, experimental science, and AI to transform and accelerate scientific research.

  • An update from our founders

    We're going all in on AI-powered biology for our next chapter.

  • Launching the first large-scale scientific initiative combining frontier AI with frontier biology to solve disease

    To power this initiative, we are uniting our scientific teams as a single organization: Biohub.

  • Genomics research for all

    VariantFormer is the first deep learning model characterizing cross-tissue gene expression by bridging sequence-based modeling across genomes with population-based modeling across personalized genomes.

  • Modeling cellular diversity

    scLDM, a deep generative AI model of transcriptomics, generates realistic single-cell data to accelerate virtual cell research.

  • The Virtual Immune System: A roadmap for predictive human immunology

    We are entering a third revolution in immunology with the ability to solve some of the hardest problems in disease, says Aly Khan, Biohub’s senior director of artificial intelligence.

  • Advancing patient-led science through collaboration

    The Rare As One Cycle 2 Impact Report highlights how patient communities are accelerating research and reshaping the rare disease landscape.